ProCE Banner Activity

POPLAR: Atezolizumab Improved Survival vs Docetaxel in Patients With Advanced NSCLC and Increasing Levels of PD-L1 Expression

Slideset Download
Conference Coverage
In an interim analysis of atezolizumab as second-line or third-line therapy for advanced NSCLC, clinical efficacy correlated with PD-L1 expression level.

Released: June 02, 2015

Expiration: May 31, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation